OxVax Ltd. is a spin-out company from the University of Oxford focused on developing an advanced next-generation dendritic cell vaccine platform for the treatment of solid tumour cancers.
The Company’s technology is based on intellectual property from the Fairchild laboratory at the Sir William Dunn School of Pathology. It exploits induced pluripotent stem cells (iPSC) as a novel source of CD141+ dendritic cells (DC), a novel proprietary subset whose unique properties make them attractive candidates for cancer immunotherapy.
The successful candidate will report to the CEO and Head of Laboratory Operations to meet the initial milestones required to develop OxVax’s proprietary cell therapy product. Initially, these involve the phenotypic and functional characterisation of dendritic cells differentiated in vitro from human iPSC, developing a range of assays to be used as release criteria for individual batches of cells and the downstream design and implementation of in vivo proof of concept experiments in appropriate animal models.
Initial responsibilities will include:
· Design and implementation of assays for the characterisation of iPSC-derived dendritic cells
· Development of appropriate Standard Operating Procedures (SOPs) for individual assays
· Maintenance of careful written records of experimental procedures
· Data analysis and the presentation of results to stakeholders
· Preparation of written progress reports for submission to investors
· Maintaining a good understanding of immuno-oncology from the scientific literature
· Participation in fund-raising activities, such as the preparation of grant applications
· Engagement with regulatory bodies including the MHRA, HTA and NHS REC
· Maintaining familiarity with current Health and Safety legislation
The candidate will assume project leadership responsibilities, managing the technology from conception to delivery, helping the company progress from the bench to patient clinical trials. The candidate is expected to help shape future research programmes of the company, aiming at developing a fully allogeneic off-the-shelf cellular vaccine product.
The successful candidate would be expected to have the following:
· Excellent practical laboratory skills
· A PhD in immunology or a closely-related field
· At least four years of post-doctoral experience
· A publication record in immunology or a related area of research
· A high level of competence in the design and successful completion of experiments
· An excellent understanding of immuno-oncology and current trends in the field
· Excellent communication skills, both spoken and written, to enable the presentation of data to stakeholders and potential investors
· Excellent organisational skills and attention to detail
· Flexibility in working hours to accommodate occasional out-of-hours work
· Prior experience of working with dendritic cells is highly desirable
· Prior experience of working with iPSC would be an advantage
· Experience of working in the biotech sector
· Familiarity with the protection of intellectual property
How to Apply
Applications should be sent by email to Marcelo Bravo CEO of OxVax at firstname.lastname@example.org and should include an up-to-date CV and a covering letter outlining the reasons for your interest in the Head of Immunology post and the relevant experience you would bring to the position. The deadline for applications is 15 June. Interviews of shortlisted candidates will be held on zoom or Microsoft Teams during the week beginning 21 June: the successful candidate will subsequently be interviewed by Dr Thomas Hanke, Board Director.